Physician profile
Lai Xu
NPI 1336585132
$9,186.21
in general payments reported to CMS, 2019-2025
70 companies · $2,403 in 2025
The $2,403 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $430 · 2021: $1,698 · 2022: $896 · 2023: $1,288 · 2024: $2,206 · 2025: $2,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,655 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,654.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $241.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $1,000.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $897.75 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $767.22 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $483.96 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Genentech USA, INC. | $452.12 | 2019-2025 | Phesgo, Itovebi, Perjeta |
| Tg Therapeutics, INC. | $407.12 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $313.60 | 2022-2025 | Opdivo, Opdualag, Eliquis |
| Lilly USA, LLC | $274.55 | 2019-2024 | Verzenio |
| Seagen INC. | $263.95 | 2020-2023 | Tukysa |
| Amgen INC. | $207.75 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Astellas Pharma US INC | $201.90 | 2021-2025 | Padcev, Xtandi |
| Daiichi Sankyo INC. | $188.26 | 2020-2024 | Enhertu |
| Celgene Corporation | $180.50 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Gilead Sciences, INC. | $176.17 | 2021-2024 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $169.97 | 2020-2025 | Fruzaqla, Iclusig, Alunbrig |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $161.61 | 2023-2025 | Orserdu |
| Genzyme Corporation | $159.42 | 2020-2025 | |
| Janssen Biotech, INC. | $156.33 | 2021-2025 | Erleada, Akeega, Balversa |
| Springworks Therapeutics, INC. | $154.82 | 2024 | Ogsiveo |
| Incyte Corporation | $145.00 | 2019-2025 | Monjuvi |
| Pfizer INC. | $137.77 | 2019-2025 | |
| Exelixis INC. | $112.74 | 2020-2024 | Cabometyx |
| Adc Therapeutics America, INC. | $109.79 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $109.42 | 2019-2023 | Imbruvica, Epkinly |
| Glaxosmithkline, LLC. | $108.78 | 2023-2025 | Jemperli, Zejula, Blenrep |
| G1 Therapeutics, INC. | $96.96 | 2022-2023 | Cosela |
| Myriad Genetic Laboratories, INC. | $92.81 | 2021 | |
| Puma Biotechnology, INC. | $89.24 | 2020-2025 | |
| Beigene USA, INC. | $87.98 | 2020-2024 | Brukinsa |
| Blueprint Medicines Corporation | $82.18 | 2020-2025 | Ayvakit |
| Abbvie INC. | $78.67 | 2022-2024 | Venclexta |
| Jazz Pharmaceuticals INC. | $74.43 | 2022-2023 | |
| Tempus Ai, INC | $72.90 | 2024-2025 | Xt Cdx |
| Servier Pharmaceuticals LLC | $72.77 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $69.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $59.73 | 2019-2023 | Xarelto |
| Novocure INC. | $57.42 | 2024-2025 | Optune Lua (Novottf-200t) |
| Deciphera Pharmaceuticals INC. | $55.41 | 2024-2025 | Qinlock, Romvimza |
| Inari Medical, INC. | $54.50 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Aveo Pharmaceuticals, INC. | $49.24 | 2022-2024 | Fotivda |
| Pharmacosmos Therapeutics INC. | $49.20 | 2022-2024 | Cosela |
| Emd Serono, INC. | $46.71 | 2022-2025 | |
| Tersera Therapeutics LLC | $42.68 | 2023-2025 | Zoladex, Xermelo |
| Karyopharm Therapeutics INC. | $41.44 | 2021-2022 | |
| Eisai INC. | $41.34 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $39.31 | 2024-2025 | |
| Caris Mpi, INC. | $35.58 | 2025 | Mi Cancer Seek |
| Amag Pharmaceuticals, INC. | $29.46 | 2021 | |
| Array Biopharma INC | $28.19 | 2025 | Lorbrena |
| Adaptive Biotechnologies Corporation | $28.06 | 2025 | Clonoseq |
| Mirati Therapeutics, INC. | $26.00 | 2024 | Krazati |
| Accord Healthcare, INC. | $24.98 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.69 | 2025 | Ultomiris |
| Agios Pharmaceuticals, INC. | $23.50 | 2024 | Pyrukynd |
| Beone Medicines USA, INC. | $23.17 | 2025 | Brukinsa |
| Immunogen, INC. | $21.71 | 2023 | Elahere |
| Coherus Oncology, INC. | $20.28 | 2021 | |
| Iovance Biotherapeutics, INC. | $20.05 | 2024 | Amtagvi |
| Cti Biopharma Corp. | $19.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.44 | 2025 | |
| Rigel Pharmaceuticals, INC. | $19.16 | 2024 | Rezlidhia, Tavalisse |
| Genmab U.S., INC. | $17.28 | 2024 | Epkinly |
| Pharmaand Gmbh | $17.16 | 2025 | Rubraca |
| Tolmar, INC. | $17.16 | 2025 | Eligard, Rubraca |
| Amneal Pharmaceuticals LLC | $16.95 | 2023 | Avastin |
| Apellis Pharmaceuticals, INC. | $15.97 | 2022 | |
| Spectrum Pharmaceuticals INC. | $15.77 | 2025 | Rolvedon |
| Dova Pharmaceuticals | $14.91 | 2021 | |
| Verastem, INC. | $12.13 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lai Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.